Progenics Pharma (PGNX) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss)
Depreciation and amortization	1.86M
Expenses for share-based compensation awards	1.96M
(Increase) decrease in accounts receivable	-403K
Decrease (increase) in other current assets
Decrease in other assets
Decrease in accounts payable and accrued expenses
Increase in deferred revenue - current
Increase in deferred revenue - long term
(Decrease) increase in other liabilities	3.5M
Net cash provided by (used in) operating activities	27.26M
Capital expenditures	-3.26M
Sales/maturities of marketable securities
Net cash provided by investing activities	-2.92M
Proceeds from the exercise of stock options and sale of common stock under the Employee Stock Purchase Plan
Net cash provided by financing activities	510K
Net increase (decrease) in cash and cash equivalents	24.79M
Cash and cash equivalents at beginning of period	74.1M
Cash and cash equivalents at end of period	98.89M

Entities mentioned with PGNX

View All Entities